A phase Ib/II clinical study of SGN-LIV1A administered in combination with atezolizumab as second-line therapy in patients with metastatic triple-negative breast cancer.

Trial Profile

A phase Ib/II clinical study of SGN-LIV1A administered in combination with atezolizumab as second-line therapy in patients with metastatic triple-negative breast cancer.

Planning
Phase of Trial: Phase I/II

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Atezolizumab (Primary) ; SGN LIV1A (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 26 Jul 2017 New trial record
    • 24 Jul 2017 According to a Seattle Genetics media release, Genentech will manage the study operations for this trial and Seattle Genetics will retain global development and commercialization rights to SGN-LIV1A.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top